227 related articles for article (PubMed ID: 23016251)
1. HPV 6, 11, 16, 18 vaccine in men. Inadequate assessment.
Prescrire Int; 2012 Sep; 21(130):208. PubMed ID: 23016251
[TBL] [Abstract][Full Text] [Related]
2. [Vaccination against HPV in adults].
Gil Á
Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():22-5. PubMed ID: 20084345
[No Abstract] [Full Text] [Related]
3. Gardasil: Introducing the new human papillomavirus vaccine.
McLemore MR
Clin J Oncol Nurs; 2006 Oct; 10(5):559-60. PubMed ID: 17063609
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
Flaherty DK; Alkhateeb FM
Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
6. Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the U.S.A., National Health and Nutrition Examination Surveys, 2003-2006.
Introcaso CE; Dunne EF; Hariri S; Panicker G; Unger ER; Markowitz LE
Sex Transm Infect; 2014 Sep; 90(6):505-8. PubMed ID: 24748563
[TBL] [Abstract][Full Text] [Related]
7. HPV 6,11,16,18 vaccine: pharmacovigilance reports in 2007.
Prescrire Int; 2008 Aug; 17(96):160. PubMed ID: 19496245
[No Abstract] [Full Text] [Related]
8. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
Villa LL; Ault KA; Giuliano AR; Costa RL; Petta CA; Andrade RP; Brown DR; Ferenczy A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson SE; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
Vaccine; 2006 Jul; 24(27-28):5571-83. PubMed ID: 16753240
[TBL] [Abstract][Full Text] [Related]
9. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
11. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
12. [Prevention of HPV-associated neoplasias by vaccination - short version of the German S3 (level 3) guideline].
Gross G; Gissmann L; Hillemanns P; Ikenberg H; Kaufmann AM; Petry KU; Pfister H; Schneede P; Schneider A; Smola S;
Dtsch Med Wochenschr; 2010 May; 135(21):1083-6. PubMed ID: 20486060
[No Abstract] [Full Text] [Related]
13. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
14. [Cervix carcinoma--Austrian Vaccination Committee recommends HPV vaccination].
Six L; Joura EA
Wien Med Wochenschr; 2007; 157(5-6):130-2. PubMed ID: 17427010
[No Abstract] [Full Text] [Related]
15. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
Marty R; Roze S; Bresse X; Largeron N; Smith-Palmer J
BMC Cancer; 2013 Jan; 13():10. PubMed ID: 23298365
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
17. CDC panel backs routine HPV vaccination.
Kuehn BM
JAMA; 2006 Aug; 296(6):640-1. PubMed ID: 16896097
[No Abstract] [Full Text] [Related]
18. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil.
Nicol AF; Grinsztejn B; Friedman RK; Veloso VG; Cunha CB; Georg I; Pilotto JH; Moreira RI; Castro CA; Silver B; Viscidi RP
J Clin Virol; 2013 Jun; 57(2):147-51. PubMed ID: 23490398
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of human papillomavirus antibodies in males and females in England.
Desai S; Chapman R; Jit M; Nichols T; Borrow R; Wilding M; Linford C; Lowndes CM; Nardone A; Pebody R; Soldan K
Sex Transm Dis; 2011 Jul; 38(7):622-9. PubMed ID: 21317688
[TBL] [Abstract][Full Text] [Related]
20. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA
J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
